Immuron Limited
IMC.ASXHealth Care
Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans relating to gastrointestinal health, liver diseases such as fatty liver/NASH and infectious diseases such as Clostridium diffi
Market Data
$0.040
-0.1%$14.4M
-100000.0x
$-0.019
0.00%
-0.4%
Latest Earnings
Appendix 4D and Half Year Report
25 February 2026
Immuron reported record half-year sales of A$4.2M, up 4.8% on the prior period, while reducing losses by 22.9% to A$1.9M. The company received FDA approval for its IMM-529 C. diff treatment and launched the PROIBS® product for IBS, with strong cash position of A$10.0M after raising capital. Key points: Record sales of A$4.2M for HY26, up 5% on HY25 with growth across Australia (11%) and USA (17%); FDA approval received for IMM-529 IND application for Phase 2 C. diff clinical trial with projected US$400M annual revenue potential; Strong cash position of A$10.0M (vs A$2.8M at June 2025) following successful capital raising
Recent Announcements
Appendix 4D and Half Year Report
Immuron reported record half-year sales of A$4.2M, up 4.8% on the prior period, while reducing losses by 22.9% to A$1.9M. The company received FDA approval for its IMM-529 C. diff treatment and launched the PROIBS® product for IBS, with strong cash position of A$10.0M after raising capital. Key points: Record sales of A$4.2M for HY26, up 5% on HY25 with growth across Australia (11%) and USA (17%); FDA approval received for IMM-529 IND application for Phase 2 C. diff clinical trial with projected US$400M annual revenue potential; Strong cash position of A$10.0M (vs A$2.8M at June 2025) following successful capital raising
Get real-time alerts for IMC
Receive AI-powered earnings summaries and instant notifications when Immuron Limited releases results.
Register Free